Nebulized Heparin for COVID19-associated Acute Respiratory Failure

Phase 2 Terminated 2 enrolled Brittany Bissell

RandomizedSingle-groupOpen-labelTreatment

Summary

The objective of the current study is to investigate the utilization of nebulized heparin to circumvent pathologic changes in COVID-19 and prevent harmful effects possible with systemic anticoagulation.

Timeline

Start: 2021-05-20
Primary completion: 2021-09-04
Completion: 2021-09-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Heparin	Other / unclassified	25000 iu	Inhaled

Nebulized Heparin for COVID19-associated Acute Respiratory Failure

Summary

Timeline

Drugs

Indications